The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Primary Central Nervous System Lymphoma

Aggressive B-cell lymphoma confined to brain, spinal cord, eyes, or leptomeninges

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Primary Central Nervous System Lymphoma?

Primary central nervous system lymphoma (PCNSL) accounts for 2-3% of all primary brain tumors and 4-6% of extranodal lymphomas, with annual incidence of 5-7 per million population. Median age at diagnosis is 65 years in immunocompetent hosts and lower in immunocompromised. Approximately 95% of PCNSL cases are diffuse large B-cell lymphoma (DLBCL) of activated B-cell subtype, with rare cases of T-cell, low-grade B-cell, Burkitt, or other variants. EBV is associated in immunodeficiency-related PCNSL but not primary PCNSL in immunocompetent patients.

Pathogenesis involves complex molecular events with mutations in MYD88 L265P (60-90%), CD79B (40-50%), TBL1XR1, CDKN2A loss, and BCL6 translocations. Pathologic features include perivascular angiocentric growth pattern, large atypical lymphoid cells with vesicular nuclei, and brisk apoptosis. Clinical features include focal neurological deficits depending on tumor location (50-80%), neuropsychiatric symptoms (cognitive impairment, behavioral changes, 20-30%), increased intracranial pressure (headache, nausea, vomiting, 30-40%), seizures (10-30%), ocular symptoms (vitritis, uveitis, 10-20%), and meningeal symptoms with leptomeningeal involvement.

Diagnosis requires brain MRI with characteristic features (typically periventricular, supratentorial, homogeneously enhancing, T2 hypointense, restricted diffusion), stereotactic brain biopsy (gold standard, typically diagnostic in single attempt), CSF analysis with cytology and flow cytometry, ophthalmologic evaluation for vitreoretinal involvement, and exclusion of systemic lymphoma with PET-CT, bone marrow biopsy, and testicular ultrasound in elderly men. Avoidance of corticosteroids before biopsy is preferred (rapid lymphocyte apoptosis can obscure diagnosis). Treatment requires combination of induction chemotherapy with high-dose methotrexate (HD-MTX) backbone, with rituximab, and consolidation with whole brain radiation therapy or autologous stem cell transplantation. Modern protocols (R-MPV, MATRix, R-MTHV) achieve 50-80% complete response rates and 50% 5-year overall survival. Whole brain radiation therapy is associated with significant neurotoxicity in elderly. Treatment of HIV-associated PCNSL has improved with antiretroviral therapy and rituximab-containing regimens.

Symptoms

Focal neurological deficits (50-80%)
Hemiparesis or hemiplegia
Cognitive impairment
Memory difficulties
Personality and behavioral changes
Confusion
Aphasia
Seizures (10-30%)
Headache (often progressive)
Nausea and vomiting
Increased intracranial pressure features
Visual symptoms (floaters, blurred vision)
Vitritis and uveitis (10-20%)
Cranial nerve palsies
Cerebellar dysfunction
Sensory deficits
Spinal cord syndromes (rare)
Leptomeningeal symptoms (rare)
B-symptoms (uncommon in PCNSL)
Papilledema

Risk Factors

HIV/AIDS infection
Solid organ transplantation
Stem cell transplantation
Immunosuppressive therapy
Common variable immunodeficiency
Other primary immunodeficiency syndromes
Older age (median 65 years in immunocompetent)
EBV infection (in immunocompromised)
Family history of lymphoma (rare)
Methotrexate therapy for autoimmune disease (rare)
Renal transplantation (highest risk among transplant)
Prior radiation therapy
Compromised T-cell function
CD4 count <50 in HIV
Lymphoproliferative disorders
Autoimmune disease
Long-term immunosuppression
Genetic susceptibility factors
Male gender (slight predominance)
Caucasian ethnicity

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Progressive focal neurological deficits
  • Cognitive decline with brain mass on imaging
  • New-onset seizures with brain mass
  • Headache with neurological signs
  • Visual changes with vitritis
  • Cranial nerve symptoms
  • Increased intracranial pressure features
  • Concerning brain MRI findings
  • HIV-positive patient with neurological symptoms
  • Post-transplant patient with brain symptoms
  • Suspected PCNSL evaluation
  • Treatment failure of presumed cerebral toxoplasmosis
  • Recurrent disease after initial treatment
  • Long-term follow-up of treated PCNSL

Treatment Methods

01
Comprehensive evaluation by neuro-oncologist or hematologist with PCNSL expertise
02
Detailed history and neurological examination
03
Brain MRI with and without contrast (essential)
04
Whole brain MRI for leptomeningeal involvement
05
Spine MRI if spinal symptoms
06
Stereotactic brain biopsy (gold standard for diagnosis)
07
Avoid corticosteroids before biopsy when possible
08
Histopathology with immunohistochemistry (CD20+, CD10±, BCL6+, MUM1+)
09
MYD88 L265P and CD79B mutation testing
10
EBV testing on tissue and CSF
11
CSF analysis with cytology, flow cytometry, IgH gene rearrangement
12
Ophthalmologic evaluation including slit-lamp, dilated fundus exam
13
Vitreal biopsy if vitritis present
14
PET-CT to exclude systemic disease
15
Bone marrow biopsy and aspirate
16
Testicular ultrasound in elderly men
17
HIV testing (essential)
18
EBV serology and DNA quantification
19
Comprehensive metabolic panel, LDH, beta-2-microglobulin
20
Cardiac function assessment for treatment planning
21
High-dose methotrexate (HD-MTX) 3-8 g/m² as backbone
22
R-MPV protocol (rituximab, methotrexate, procarbazine, vincristine)
23
MATRix protocol (rituximab, methotrexate, thiotepa, cytarabine)
24
R-MTHV (rituximab, methotrexate, temozolomide, vincristine)
25
CNS-penetrating chemotherapy (high-dose cytarabine, ifosfamide, thiotepa)
26
Consolidation with whole brain radiation therapy (WBRT) or autologous SCT
27
Reduced-dose WBRT to minimize neurotoxicity
28
Autologous stem cell transplantation in fit patients (preferred over WBRT)
29
Maintenance therapy considerations
30
Treatment of relapsed disease with salvage chemotherapy or transplant
31
Lenalidomide and ibrutinib for refractory disease
32
Concurrent ART for HIV-associated PCNSL
33
Symptomatic management with corticosteroids (after diagnosis)
34
Anticonvulsants for seizures
35
Multidisciplinary care including neurology, ophthalmology, infectious disease
36
Long-term cognitive and neurological monitoring
37
Supportive care for neurotoxicity

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.